title: Toll-like receptor therapies compete to reduce side effects.
authors.forename: Charlie
authors.initials: C
authors.lastname: Schmidt
mesh_terms: D006801:Humans; D007113:Immunity, Innate; D007155:Immunologic Factors / Q000378:metabolism*; D007167:Immunotherapy / Q000009:adverse effects*; D009369:Neoplasms / Q000628:therapy; D051193:Toll-Like Receptors / Q000378:metabolism / Q000627:therapeutic use*
chemical_list: D007155:Immunologic Factors; D051193:Toll-Like Receptors